RxDoctor Payments Data

Eric Bloemer, MD

Family Medicine · Teutopolis, ILNPI 1073742664

Payments from drug & device makers

$1,452in general payments, 2019–2025

Across 81 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$255
  • Amgen$176
  • Lilly USA, LLC$175
  • Boehringer Ingelheim$134
  • Organon$123
  • Johnson & Johnson$110
  • plus $478 from 15 others

What the payments were for

  • Food & beverage$1,452100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,452 in reported general payments places this provider in the 75th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$108,939
Medicare patients
637
Services billed
1,778

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban645$426,093
MounjaroTirzepatide104$117,216
XareltoRivaroxaban131$111,349
JanuviaSitagliptin Phosphate148$108,413
OzempicSemaglutide100$108,292
JardianceEmpagliflozin121$85,251
TrulicityDulaglutide76$78,639
Tresiba Flextouch U-200Insulin Degludec45$43,813
ProliaDenosumab25$43,374
EntrestoSacubitril/Valsartan55$35,012
TradjentaLinagliptin30$30,032
FarxigaDapagliflozin Propanediol29$24,443
Humalog Kwikpen U-100Insulin Lispro48$18,028
ShingrixVaricella-Zoster Ge/As01b/Pf77$16,155
Lantus SolostarInsulin Glargine,hum.Rec.Anlog105$15,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$426,093645 claims
Lilly USA, LLCMounjaro, Trulicity$175$195,856180 claims
MerckJanuvia, Dulera, Janumet$41$131,131205 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$134$122,340165 claims
Novo NordiskOzempic, Rybelsus$255$119,839112 claims
Johnson & JohnsonXarelto$110$111,349131 claims
AmgenProlia$176$43,37425 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$78$37,71166 claims
NovartisEntresto$29$35,01255 claims
AbbVieLinzess, Creon$12$24,39263 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Teutopolis

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →